Patients with AT were younger and less frequently hypertensive. Glycoprotein IIb/IIIa inhibitors were more frequently administrated in the AT group. However, a decrease in the rate of patients with TIMI 3 flow grade post PCI was observed in the AT group. Peak creatine kinase was significantly higher in patients with AT while ischemic time was similar for the 2 groups. Stenting the infarct-related lesion was less frequent than in the control group. CV mortality at 30 days and at 1-year were higher in the AT group (11.4 vs. 5.2 %, p=0.016, and 14.6 vs. 7%, p=0.013) respectively. By multivariate analysis, AT remains an independent predictor of 1-Y mortality even when adjusted for potential confounders (HR(95%CI):4.95(2.08-11.77)). These results were unchanged when the propensity score for AT was introduced into the model.
Is it Safe to use Drug Eluting Stents in Older patients? Lessons from the PAPI registry
Patrick Dupouy (1), Michel Hanssen (2), Emmanuel Teiger (3), Michel Slama (4), Olivier Wittenberg (5), Janusz Lipiecki (6) (1) PCVI Hopital Prive d'Antony, Antony, Haguenau, Hopital Henri Mondor APHP, Creteil, France -(4) HOpital Antoine Beclere Aphp, Clamart, France -(5) Centre Hospitalier Prive Beauregard, Marseille, France -(6) Hopital Gabriel Montpied-Groupe Hospitalier St Jacques-CHU, Clermont-Ferrand, France Background: Elderly patients are at higher risk for coronary angioplasty and few data exist on the safety of drug eluting stent (DES) in this special population. Objectives: this registry sought to compare bare metal stent (BMS) and DES short and long term clinical outcome and survival in a cohort of patients older than 75.
Methods: between September 2007 and august 2008, 2000 patients older than 75 years old were included in a prospective the multicentric PAPI registry. Patients were all treated by coronary stenting with either BMS or DES and were followed for clinical events at the end of the initial hospitalisation, at 6, 12 and 24 months. Patients were compared according to there DES/ BMS status for the entire cohort and were divided in 3 subgroups according to there age 75-80, 80-85 and >85 to assess aging influence.
Results: mean age of the total population was 80±3 (75-96). On the overall population 3318 stents were used for the angioplasty of 3132 lesions. Twenty seven percent of them were DES. There was a significant decrease of DES use in older patients (12% patients >85 vs 33% patients <80 p=0.0001). At 6 month death occured in 3.2% of patients, infarction in 1.5% and stent thrombosis in 1.5% with no significant difference between type of stent. There was a trend for less Major Adverse Cardiac events (MACE) in DES patients (6% vs 8%; p=0.07) and significantly less Major Adverse Cardiac and CerebroVascular events (MACCE) in DES patients (6% vs 9%; p=0.02). There was less major events for DES than for BMS patients for the younger group (7%vs13%; p=0.01). In uni or multivariate analysis stent type was not predictive of adverse event.
Conclusion: PAPI is a multicentric prospective registry aim to evaluate the outcome of modern coronary angioplasty in patients > 75 years old. DES were associated with a significant better outcome at 6 month. Thus, at least at 6 month, the use of DES in older patients seems to be safe in older patients. 
